- Levitee Labs (LVT) will issue up to 15,000,000 units at a price of $0.20 per unit for gross proceeds of up to $3,000,000
- Each unit will include one common share and one share purchase warrant
- Proceeds raised will be used to strengthen the company’s balance sheet and to drive growth
- Levitee operates in the integrative wellness space with a focus on psychedelic medicines and therapies
- Levitee Labs Inc. (LVT) opened trading at C$0.235 per share
Levitee Labs (LVT) has announced a non-brokered private placement for gross proceeds of up to $3,000,000.
The company will issue up to 15,000,000 units at a price of $0.20 per unit. Each unit will include one common share and one share purchase warrant. Each warrant will be exercisable at $0.40 per share for a period of 24 months.
Levitee Labs will pay a finder’s fee of 8 per cent and will issue finder’s warrants equal to 8 per cent of the units sold to subscribers introduced by certain finders.
“We are excited to move forward with our strategic growth objectives,” said Pouya Farmand, CEO of Levitee Labs.
“Through this financing we will have the balance sheet strength to further grow the company and focus on our mission to bring innovative treatments to addiction services patients,” Mr. Farmand added.
Levitee operates in the integrative wellness space with a focus on psychedelic medicines and therapies.
Levitee Labs Inc. (LVT) opened trading at C$0.235 per share.
